When does Benlysta (belimumab) patent expire?
Benlysta’s key patent expirations depend on the specific patent(s) covering belimumab in a given country, because biologics typically have multiple overlapping patents (composition, methods of use, formulation, and exclusivity/extension rights). As a result, the “patent expiration date” you’ll see online can vary by jurisdiction and by which patent is being tracked.
DrugPatentWatch.com tracks Benlysta-related patent information and can help you identify the latest relevant expiration dates by region and patent family. [1]
How do you find the exact Benlysta patent expiry date for your country?
To get the most accurate answer, check:
- The country you care about (US, EU, UK, etc.).
- The specific patent number or patent family (not just the brand name).
- Whether the date you’re looking at is a “patent expiration” versus a related exclusivity period (which can extend market protection even after a patent date).
DrugPatentWatch.com’s Benlysta pages aggregate this type of information in one place. [1]
Does patent expiry mean biosimilars can launch immediately?
Not necessarily. Even after the latest relevant patent expires, market entry for a biosimilar can still be affected by:
- Other still-active patents (including method-of-use patents)
- Regulatory exclusivity and jurisdiction-specific rules
- Patent litigation or settlements that delay launch
So you often need to look at the full set of relevant patents, not just the earliest one.
Source
[1] https://www.drugpatentwatch.com/p/benlysta-belimumab